SCHEMBL1339155

SCHEMBL1339155

Nc1cc(Cl)ccc1Oc1ccccc1Cl

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.66
CYP1A2 P05177 2/20 0.66
CYP2C9 P11712 2/20 0.66
CYP2C19 P33261 2/20 0.66
MAPT P10636 6/20 0.58
LMNA P02545 3/20 0.58
HTT P42858 2/20 0.58
HPGD P15428 4/20 0.58
ALDH1A1 P00352 3/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
KDM4E B2RXH2 2/20 0.58
MEN1 O00255 1/20 0.58
CYP2D6 P10635 1/20 0.58
KMT2A Q03164 1/20 0.58
L3MBTL1 Q9Y468 2/20 0.53
TSHR P16473 4/20 0.47
TP53 P04637 1/20 0.47
SLC6A2 P23975 3/20 0.46
SLC6A3 Q01959 3/20 0.46
SLC6A4 P31645 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3652668 0.86 MAPT (0.63) CYP3A4CYP1A2CYP2C9CYP2C19MAPT
SCHEMBL5863619 0.86 MAPT (0.73) CYP3A4CYP1A2CYP2C9CYP2C19MAPT
SCHEMBL11053300 0.86 CYP3A4 (0.57) CYP3A4CYP1A2CYP2C9CYP2C19MAPT
SCHEMBL641111 0.85 CYP2C9 (0.56) CYP3A4CYP1A2CYP2C9CYP2C19MAPT
Hydrochloric Acid SCHEMBL11346813 0.85 MAPT (0.67) CYP3A4CYP1A2CYP2C9CYP2C19MAPT
Hydrochloric Acid SCHEMBL2884722 0.84 CYP2C9 (0.54) CYP3A4CYP1A2CYP2C9CYP2C19MAPT
SCHEMBL1340366 0.83 L3MBTL1 (0.59) CYP3A4CYP1A2CYP2C9CYP2C19MAPT
SCHEMBL9266509 0.82 TSHR (0.54) CYP3A4CYP1A2CYP2C19MAPTLMNA
SCHEMBL30379539 0.82 TSHR (0.54) CYP3A4CYP1A2CYP2C19MAPTLMNA
Nitrogen SCHEMBL28057126 0.82 MAPT (0.68) CYP3A4CYP1A2CYP2C9CYP2C19MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE45670-E1 Aryl carbonyl derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2015-09-15 US disclosed
CN-101130526-B Aryl carbonyl derivatives as therapeutic agents NOVO NORDISK AS 2013-07-10 CN disclosed
EP-2471533-A1 Aryl carbonyl derivatives as therapeutic agents Novo Nordisk A/S (DK) 2012-07-04 EP disclosed
US-20110301158-A1 ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS NOVO NORDISK A/S (DK) 2011-12-08 US disclosed
US-8063081-B2 N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-11-22 US disclosed
US-7897628-B2 {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-03-01 US disclosed
CN-101830766-A Synthesis method of amino aromatic ether compound SHUANGHONG CHEMICAL CO LTD 2010-09-15 CN disclosed
US-7541373-B2 Aryl carbonyl derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2009-06-02 US disclosed
US-20080293720-A1 Pyridinyl Sulfonamide Modulators of Chemokine Receptors GLAXO GROUP LIMITED (GB) 2008-11-27 US disclosed
US-7384967-B2 Aryl carbonyl derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2008-06-10 US disclosed
US-4874391-A USING WATER SOLUBLE COPPER COMPLEX AZO DYE, LIGHT STABILIZER AND ANTIOXIDANT CIBA-GEIGY CORPORATION (US) 1989-10-17 US disclosed
US-4813972-A USING LEVELING DYES, COLORFASTNESS CIBA-GEIGY CORPORATION (US) 1989-03-21 US disclosed
EP-0280156-A2 Process for the preparation of acetoacetylarylamides-heteroarylamides respectively of deactived aromatic compounds HOECHST AKTIENGESELLSCHAFT (DE) 1988-08-31 EP disclosed
US-4723001-A Fibre-reactive chromium complexes and their preparation and use CIBA-GEIGY CORPORATION (US) 1988-02-02 US disclosed
US-4704133-A FIBER-REACTIVE CIBA-GEIGY CORPORATION (US) 1987-11-03 US disclosed
US-4680385-A Metal dye complexes containing an azo or azomethine dye and a colorless ligand with the C═N--N═C group CIBA-GEIGY CORPORATION (US) 1987-07-14 US disclosed
US-4678851-A FIBER-RACTIVE CIBA-GEIGY CORPORATION (US) 1987-07-07 US disclosed
EP-0121495-B1 MONOAZO DYESTUFFS, THEIR PREPARATION AND THEIR USE CIBA-GEIGY AG (CH) 1986-12-17 EP disclosed
US-4602961-A MONOAZO BENZOTHIAZOLE DERIVATIVES CIBA-GEIGY CORPORATION (US) 1986-07-29 US disclosed
EP-0121495-A1 Monoazo dyestuffs, their preparation and their use CIBA-GEIGY AG (CH) 1984-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301158-A1 ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS GCK, GCKR, PDK2 CYP3A4 977/4885CYP1A2 982/4885CYP2C9 1824/4885
US-20080293720-A1 Pyridinyl Sulfonamide Modulators of Chemokine Receptors CCR2, CCR1, CCRL2 CYP3A4 1414/4885CYP1A2 898/4885CYP2C9 1296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.